Recent Research Advance to Differentiate Portal Hypertension Associated with Primary Myelofibrosis and Cirrhosis --Review.
10.19746/j.cnki.issn.1009-2137.2023.02.043
- Author:
Rui LI
1
;
Hua-Sheng LIU
2
;
Ying CHEN
1
Author Information
1. Department of Hematology， The First Affiliated Hospital of Xi'an Jiaotong University. Xi'an 710061, Shaanxi Province, China.
2. Department of Hematology， The First Affiliated Hospital of Xi'an Jiaotong University. Xi'an 710061, Shaanxi Province, China. E-mail：Lhs681995@126.com.
- Publication Type:Journal Article
- Keywords:
bone marrow;
liver;
fibrosis;
hypertension;
portal vein;
splenomegaly
- MeSH:
Humans;
Primary Myelofibrosis/drug therapy*;
Hypertension, Portal/complications*;
Liver Cirrhosis/pathology*;
Splenomegaly/pathology*;
Anemia
- From:
Journal of Experimental Hematology
2023;31(2):598-601
- CountryChina
- Language:Chinese
-
Abstract:
Primary myelofibrosis (PMF) is easily confused with cirrhosis, due to its main clinical manifestations of splenomegaly and the blood cytopenia. This review focuses on clinical studies to identify primary myelofibrosis and cirrhosis related portal hypertension, to analyze the differences between the two diseases, in order to distinguish PMF and cirrhosis from the pathogenesis, clinical manifestations, laboratory examinations and treatment principles, and simultaneously improve clinicians' understanding of PMF, which is a reference for exploring the early screening or diagnostic indicators of PMF, also provides a clinical basis for the application of new targeted drugs such as ruxolitinib.
